Latest News

AstraZeneca completes sale of heart failure treatment commercial rights for US$400mln


AstraZeneca PLC (LON:AZN) has announced the sale of commercial rights for its Atacand and Atacand Plus drugs for US$400mln was completed.

Atacand is a prescription medicine approved for the treatment of heart failure and hypertension, while Atacand Plus is only for hypertension.

READ: AstraZeneca and Oxford University COVID-19 vaccine given UK go-ahead

The buyer is German pharma company Cheplapharm, which has paid US$250mln on completion of the deal and will pay the remainder in the first half of 2021.

In 2019, the two drugs generated sales of US$148mln and profit before tax of US$89mln in the over 70 countries covered by the agreement.

AstraZeneca will continue to manufacture and supply Atacand and AtacandPlus and will continue to commercialise them during a three-year transition period.

The FTSE 100 firm said the divestment will be recognised as other operating income in the fourth-quarter results.

Well Watch 2021 – The small oilers waiting on big drill news in the coming year

Previous article

FTSE 100 continues its breakout as lockdowns loom; US markets take a dive

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News